ACRO Biomedical Co., Ltd. (TPEX:6748)

Taiwan · Delayed Price · Currency is TWD

187.50

-8.00 (-4.09%)

Jul 9, 2026, 1:05 PM CST

394.07% (1Y)

Market Cap	13.25B +484.8%
Revenue (ttm)	38.26M -13.5%
Net Income	-82.66M
EPS	-1.35
Shares Out	71.22M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,040,819
Open	198.50
Previous Close	195.50
Day's Range	183.50 - 198.50
52-Week Range	37.25 - 202.00
Beta	0.20
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 11, 2026

About ACRO Biomedical

ACRO Biomedical Co., Ltd. develops medical-grade regenerative biomaterials in Taiwan, Vietnam, and internationally. The company engages in manufacturing medical devices and cosmetics; research, design, production, and sales of biological tissue implants; and dental and orthopedic implants, collagen, and related derivative products. It also offers products in the areas of wound care, orthopedics, dentistry, ophthalmology, cosmetic micro plastic surgery, beauty and eye care, and tissue engineering and regenerative medicines. ACRO Biomedical Co., ... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2014

Country Taiwan

Stock Exchange Taipei Exchange

Ticker Symbol 6748

Full Company Profile

Financial Performance

In 2025, ACRO Biomedical's revenue was 38.26 million, a decrease of -13.51% compared to the previous year's 44.23 million. Losses were -82.66 million, 33.1% more than in 2024.

Financial Statements